Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class i PI3K inhibitor, in patients with advanced solid tumors AC

Clinical Cancer Research

Volumn 20, Issue 1, 2014, Pages 233-245

  Shapiro, Geoffrey I ^a   Rodon, Jordi ^d   Bedell, Cynthia ^e   Kwak, Eunice L ^b   Baselga, Jose ^d   Braña, Irene ^d   Pandya, Shuchi S ^c   Scheffold, Christian ^f   Laird, A Douglas ^f   Nguyen, Linh T ^f   Xu, Yi ^g,h   Egile, Coumaran ^g,h   Edelman, Gerald ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Acceleron Pharma   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Mary Crowley Cancer Research Centers   (United States)

^f EXELIXIS INC   (United States)

^g SANOFI   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; XL 147;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLOOD SAMPLING; BODY WEIGHT DISORDER; CANCER TISSUE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAIR; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; HYPOTENSION; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR MECHANICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN; SKIN EXFOLIATION; SKIN FISSURE; SKIN TOXICITY; SOLID TUMOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASE; QUINOXALINES; SIGNAL TRANSDUCTION; SKIN DISEASES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84892181757     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1777     Document Type: Article

References (28)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
3. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
4. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-96.
5. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstreamofGprotein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008;105:8292-7.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
7. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012;18:3791-802.
8. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
9. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32.
10. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67.
11. Braccini L, Ciraolo E, Martini M, Pirali T, Germena G, Rolfo K, et al. PI3K keeps the balance between metabolism and cancer. Adv Biol Regul 2012;52:389-405.
12. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012;3:954-87.
13. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 2009;21:185-93.
14. Priulla M, Calastretti A, Bruno P, Azzariti A, Paradiso A, Canti G, et al. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 2007;67:782-9.
15. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011;71:1081-91.
16. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
17. Edelman G, Bedell C, Shapiro GI, Pandya SS, Kwak EL, Scheffold C , et al. A phase 1 dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients with adavanced malignancies. J Clin Oncol 28, 2010 (suppl; abstr A3004).
18. Sidhu SS, Egile C, Malfilatre M, Lefranc C, Ruffin Y, Ma J, et al. Antitumor activity of pimasertib in combination with SAR245409 or SAR245408 in human primary colorectal cancer xenograft models bearing PI3K/KRAS and KRAS mutations [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr A4638.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
20. Li C, Takahashi C, Zhang L, Huseni M, Stankovich B, Mashhedi H, et al. Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma. J Transl Med 2013;11:76.
21. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30:282-90.
22. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012;18:4173-82.
23. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-95.
24. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74.
25. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012; 11:317-28.
26. Gonzalez-Angulo AM, Juric D, aArgiles G, Schellens JHM, Burrris HA, Berlin J, et al. Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: results from the first-in-human study. J Clin Oncol 31, 2013 (suppl; abstr A2531).
27. Juric D, Krop I, Ramanathan RK, Xiao J, Sanabria S, Wilson TR, et al. GDC-0032, a beta isoform-sparing PI3K inhibitor: results of a first-inhuman phase Ia dose escalation study [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr LB-64.
28. Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One 2013;8:e53292.